Lazniewska, Joanna
Li, Ka Lok
Johnson, Ian R. D.
Sorvina, Alexandra
Logan, Jessica M.
Martini, Carmela
Moore, Courtney
Ung, Ben S.-Y.
Karageorgos, Litsa
Hickey, Shane M.
Prabhakaran, Sarita
Heatlie, Jessica K.
Brooks, Robert D.
Huzzell, Chelsea
Warnock, Nicholas I.
Ward, Mark P.
Mohammed, Bashir
Tewari, Prerna
Martin, Cara
O’Toole, Sharon
Edgerton, Laura Bogue
Bates, Mark
Moretti, Paul
Pitson, Stuart M.
Selemidis, Stavros
Butler, Lisa M.
O’Leary, John J.
Brooks, Douglas A.
Funding for this research was provided by:
Envision Sciences Pty Ltd
NHMRC development grant (GNT1092904)
Movember Foundation/PCa Foundation of Australia’s Research Program
MTP Connect Biomedical Translation Bridge Program grant (BTBR200074)
Cancer Council SA Beat Cancer Grant
Cancer Council of SA Beat Cancer Principal Research Fellowship (PRF1117)
Article History
Received: 15 March 2023
Accepted: 9 August 2023
First Online: 18 August 2023
Competing interests
: D.A.B. and J.O’L. are shareholders for Envision Sciences Pty Ltd and benefit from this company’s research funding. D.A.B., I.R.D.J. and L.M.B. have a patent WO2014197937A1 that has been licensed by UniSA Ventures to Envision Sciences Pty Ltd for commercialization. D.A.B. has an additional patent PCT/AU2020/050925 involving the biomarkers in this manuscript, which is owned by Envision Sciences Pty Ltd. A.S., C.Martini, S.P., J.M.L., B.S-Y.U., C.Moore, R.D.B., S.M.H., I.R.D.J., C.H. and J.L., are employed by the University of South Australia using funding from Envision Sciences Pty Ltd.